Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia

Adam Deane, Marianne Chapman, Robert Fraser, Matthew Summers, Antony Zaknic, James Storey, Karen Jones, Christopher Rayner, Michael Horowitz

    Research output: Contribution to journalArticle

    66 Citations (Scopus)

    Abstract

    Objective: To determine the acute effects of exogenous glucagon-like peptide-1 on gastric emptying, glucose absorption, glycemia, plasma insulin, and glucagon in critically ill patients. Design: Randomized, double-blind, crossover study. Setting: Intensive care unit. Subjects: Twenty-five mechanically ventilated patients, without known diabetes, studied on consecutive days. Interventions: Intravenous glucagon-like peptide-1 (1.2 pmol/kg/min) or placebo was infused between-30 and 330 mins. At 0 min, 100 mL liquid nutrient (1 kcal/mL) including 100 μg of C-octanoic acid and 3 grams of 3-O-methyl-glucose was administered. Measurements and main results: Blood glucose, serum 3-O-methyl-glucose (as an index of glucose absorption), insulin and glucagon concentrations, as well as exhaled CO2 were measured. The gastric emptying coefficient was calculated to quantify gastric emptying. Data are presented as mean (sd). There was a nonsignificant trend for glucagon-like peptide-1 to slow gastric emptying (gastric emptying coefficient) (glucagon-like peptide-1, 2.45 [0.93] vs. placebo, 2.75 [0.83]; p =.09). In 11 of the 25 patients, gastric emptying was delayed during placebo infusion and glucagon-like peptide-1 had no detectable effect on gastric emptying in this group (1.92 [0.82] vs. 1.90 [0.68]; p =.96). In contrast, in patients who had normal gastric emptying during placebo, glucagon-like peptide-1 slowed gastric emptying substantially (2.86 [0.58] vs. 3.41 [0.37]; p =.006). Glucagon-like peptide-1 markedly reduced the rate of glucose absorption (3-O-methyl-glucose area under the curve0-330, 37 [35] vs. 76 [51] mmol/L/min; p <.001), decreased preprandial glucagon (at 0 min change in glucagon,-15 [15] vs.-3 [14] pmol/L; p <.001), increased the insulin/glucose ratio throughout the infusion (area under the curve-30-330, 1374 [814] vs. 1172 [649] mU/mmol/min; p =.041), and attenuated the glycemic response to the meal (glucose area under the curve0-330, 2071 [353] vs. 2419 [594] mmol/L/min; p =.001). Conclusions: Exogenous glucagon-like peptide-1 lowers postprandial glycemia in the critically ill. This may occur, at least in part, by slowing gastric emptying when the latter is normal but not when it is delayed.

    Original languageEnglish
    Pages (from-to)1261-1269
    Number of pages9
    JournalCritical Care Medicine
    Volume38
    Issue number5
    DOIs
    Publication statusPublished - May 2010

    Keywords

    • Blood glucose
    • Critical illness
    • Enteral nutrition
    • Gastric emptying
    • Glucagon-like peptide 1
    • Hyperglycemia

    Fingerprint Dive into the research topics of 'Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia'. Together they form a unique fingerprint.

  • Cite this